Journal article
Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review
Inflammopharmacology, v 31(4), pp 1647-1656
Aug 2023
PMID: 37261626
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Statins are the primary pharmacological intervention to reduce LDL cholesterol; they significantly reduce inflammatory markers. Ezetimibe also reduces LDL cholesterol and reduces cardiovascular events when given on top of statin therapy. Whether ezetimibe, like statins, reduces markers of inflammation is less clear. We, therefore, conducted a systematic literature research addressing the impact of ezetimibe on CRP, TNFα and IL-6 when given on top of statin therapy. Our work indicates that overall ezetimibe reduces inflammation on top of statin treatment. However, available data are limited for CRP and even more so for TNFα and IL-6.
Metrics
1 Record Views
Details
- Title
- Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review
- Creators
- Margaretha Klement - Private University of the Principality of Liechtenstein, Triesen, LiechtensteinHeinz Drexel - Drexel UniversityChristoph H Saely - Department of Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria. vivit@lkhf.at
- Publication Details
- Inflammopharmacology, v 31(4), pp 1647-1656
- Publisher
- Springer Nature
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001000322600004
- Scopus ID
- 2-s2.0-85160855883
- Other Identifier
- 991022207055504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Immunology
- Pharmacology & Pharmacy
- Toxicology